Developer docs
API playgroundTry for free, no card

Search company profiles

RedHill Biopharma

Full company profile

uuid0000wme

Namestring
RedHill Biopharma
Legal namestring
RedHill Biopharma Ltd.
Websiteurl
redhillbio.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company, founded in 2009 and listed on NASDAQ under ticker RDHL, that develops and commercializes proprietary oral small molecule therapeutics for gastrointestinal, infectious, and oncological diseases. Its sole commercial product is Talicia, an FDA-approved oral fixed-dose combination of omeprazole magnesium, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection in adults, listed as a first-line therapy in the 2024 American College of Gastroenterology Clinical Guideline and protected by composition patents through 2042.

The clinical pipeline is anchored by opaganib (ABC294640/Yeliva), a first-in-class investigational oral sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anti-cancer activity, administered to over 470 participants across studies and pursuing indications including prostate cancer (Phase 2 with Bayer/darolutamide), neuroblastoma, cholangiocarcinoma, triple-negative breast cancer, CLL, and Ebola virus disease under FDA Animal Rule development funded by BARDA. Additional pipeline assets include RHB-204 (next-generation oral fixed-dose antibiotic combination targeting MAP-positive Crohn's disease, with FDA Fast Track, Orphan, and QIDP designations), RHB-107/upamostat (a once-daily oral serine protease inhibitor for viral infections and oncology, including pancreatic cancer under Orphan Drug Designation), and RHB-102/Bekinda (extended-release ondansetron for gastroenteritis, gastritis, IBS-D, GLP-1-associated GI intolerance, and oncology-support CINV/RINV indications).

The business model combines Talicia product sales — co-commercialized in the U.S. with Cumberland Pharmaceuticals under a 50/50 net-revenue-share through Talicia Holdings Inc. (in which Cumberland holds a 30% equity stake) — with licensing/milestone revenue (up to $60 million from Hyloris for RHB-102 ex-North America), non-dilutive government funding (BARDA contract for opaganib Ebola development), and recurring equity financings (public offerings, registered direct offerings, convertible notes, and strategic private placements). The company maintains a dual operating footprint with headquarters in Tel Aviv, Israel and U.S. commercial operations in Raleigh, North Carolina.

Short descriptiontext

RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company that develops and commercializes oral small molecule therapeutics for gastrointestinal, infectious, and oncological diseases, with one FDA-approved product (Talicia) and a mid-to-late-stage pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty biopharmaceuticals, gastrointestinal therapeutics, infectious disease drugs, oral small molecules, oncology drug development
Industry3 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (Gastroenterology/Infectious Diseases)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Talicia Product Sales
TypeOthers
Description

Revenue from U.S. sales of Talicia, an FDA-approved treatment for H. pylori infection, co-commercialized with Cumberland Pharmaceuticals with equal net revenue sharing.

prnewswire.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Potential milestone payments and royalties from licensing agreements, including up to $60 million from Hyloris for RHB-102 commercialization outside North America.

prnewswire.com
3Government Funding
TypeOthers
Description

U.S. government funding through BARDA for development of opaganib as a medical countermeasure for Ebola virus disease under the FDA Animal Rule pathway.

prnewswire.com
4Strategic Investment
TypeOthers
Description

Investment proceeds from private placements and strategic investments, including $4 million from Cumberland Pharmaceuticals for 30% stake in Talicia Holdings Inc.

prnewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Talicia
Description

FDA-approved treatment for Helicobacter pylori infection in adults. Oral capsule containing omeprazole magnesium, amoxicillin, and rifabutin. Co-commercialized in U.S. with Cumberland Pharmaceuticals.

redhillbio.com
Core offering1 text field

RedHill Biopharma is a specialty biopharmaceutical company that develops and commercializes proprietary oral small molecule drugs primarily targeting gastrointestinal and infectious diseases, with an expanding pipeline in oncology. The company markets Talicia, an FDA-approved oral fixed-dose combination therapy for H. pylori infection, in the U.S. and UAE, and develops a pipeline of investigational candidates including opaganib (SPHK2 inhibitor), RHB-204 (Crohn's disease antibiotic combination), RHB-107 (serine protease inhibitor), and RHB-102/Bekinda (ondansetron formulation).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Opaganib demonstrated 70.2% mortality reduction in Phase 3 COVID-19 study
+3 more records
Product overview1 text field

RedHill Biopharma is a specialty pharmaceutical company with a portfolio of proprietary oral small molecule drugs. The core commercial product is Talicia®, an FDA-approved treatment for H. pylori infection co-commercialized with Cumberland Pharmaceuticals. The R&D pipeline includes: opaganib (first-in-class SPHK2 inhibitor for oncology, viral, and metabolic diseases), RHB-204 (next-generation antibiotic for Crohn's disease), RHB-107 (serine protease inhibitor for viral infections and oncology), and RHB-102/Bekinda® (ondansetron formulation for GI disorders and oncology support). The company focuses on gastroenterology, infectious diseases, and oncology with mid-to-late-stage clinical development programs.

Product and service5 records
1Talicia
CategoryCore Commercial Product (Gastroenterology / Infectious Disease)
Description

FDA-approved prescription oral capsule combining omeprazole magnesium, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection in adults. Co-commercialized in the U.S. with Cumberland Pharmaceuticals and distributed through retail pharmacies in the U.S. and UAE.

2Opaganib (ABC294640, Yeliva)
CategoryPipeline Asset (Oncology / Infectious Disease)
Description

Proprietary first-in-class investigational oral sphingosine kinase-2 (SPHK2) selective inhibitor being developed for multiple oncology, viral, inflammatory, and metabolic indications including prostate cancer, neuroblastoma, cholangiocarcinoma, COVID-19, Ebola virus disease, triple-negative breast cancer, and CLL. Holds FDA Orphan Drug Designations for neuroblastoma and cholangiocarcinoma, and Rare Pediatric Disease Designation for neuroblastoma.

3RHB-204
CategoryPipeline Asset (Gastroenterology / Infectious Disease)
Description

Investigational next-generation fixed-dose oral antibiotic combination of clarithromycin, rifabutin, and clofazimine targeting Crohn's disease in MAP-positive patients. Optimized dosing profile from predecessor RHB-104 for enhanced tolerability, safety, and adherence.

4RHB-107 (Upamostat)
CategoryPipeline Asset (Infectious Disease / Oncology)
Description

First-in-class once-daily oral serine protease inhibitor being developed for viral infections (including COVID-19 and influenza), oncology (pancreatic cancer), and inflammatory gastrointestinal diseases. Host-directed antiviral targeting host cell factors involved in preparing spike protein for viral entry.

5RHB-102 (Bekinda)
CategoryPipeline Asset (Gastroenterology / Oncology Support)
Description

Proprietary bimodal immediate and extended-release once-daily oral ondansetron tablet (5-HT3 antagonist) targeting gastroenteritis, gastritis, IBS-D, GLP-1/GIP-associated GI intolerance, and oncology support indications including chemotherapy-induced and radiation-induced nausea and vomiting (CINV/RINV). Pursuing FDA approval through 505(b)(2) regulatory pathway.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Research collaboration for preclinical studies demonstrating opaganib's effects in neuroblastoma models, showing enhancement of chemotherapy efficacy by destabilizing n-Myc oncogenic driver.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Research collaboration showing pre-treatment with opaganib followed by low-dose diABZI potentiates STING-mediated effects and may augment anti-tumor immunity in triple-negative breast cancer.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-10-01
Description

Strategic partnership including $4 million investment for 30% equity stake in newly formed Talicia Holdings Inc. and U.S. co-commercialization agreement for Talicia. Cumberland handles distribution and sales while sharing net revenues equally with RedHill. Partnership aims to enhance Talicia's market penetration and operational efficiency in the U.S.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-02-01
Description

Exclusive worldwide development and commercialization licensing agreement, excluding North America, for RHB-102 (Bekinda). RedHill receives up to $60 million in potential milestone payments plus royalties. Hyloris advances development for oncology support (CINV/RINV) in the UK and other territories.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Bayer provides financial support for Phase 2 study evaluating opaganib in combination with Bayer's darolutamide in men with metastatic castration-resistant prostate cancer (mCRPC). Study led by Professor Lisa Horvath from Chris O'Brien Lifehouse and ANZUP cancer trials group.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research foundation supporting the Phase 2 study of opaganib in combination with darolutamide for advanced prostate cancer.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trials group leading the Phase 2 study of opaganib in advanced prostate cancer, registered with Australian New Zealand Clinical Trials Registry.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cumberland is RedHill's direct U.S. co-commercialization partner for Talicia and holds a 30% equity stake in Talicia Holdings Inc. Both are small-cap U.S.-focused specialty pharmaceutical companies targeting gastroenterology and infectious disease, with similar sales models and pipeline-heavy business profiles.

TypeDirect peer
Description

Phathom directly competes with RedHill in H. pylori infection with Voquezna (vonoprazan-based regimens), a newer branded alternative to Talicia. Both companies are U.S.-focused specialty pharma players concentrating on gastroenterology with first-line guideline-listed therapies.

TypeDirect peer
Description

Hyloris is RedHill's worldwide ex-North America licensing partner for RHB-102 (Bekinda) and operates a similar business model: a small specialty pharma that in-licenses, reformulates, and partners established molecules for niche indications. The two share a comparable pipeline-light, partnership-heavy commercialization approach.

TypeDirect peer
Description

Eagle Pharmaceuticals is a small-cap specialty pharma with similar business model attributes (505(b)(2) reformulations, hospital/specialty channels) and is led by executives who previously held senior roles at RedHill, including former CBO Guy Goldberg. Direct overlap in specialty injectable and hospital-focused product strategies.

TypeDirect peer
Description

ANI is a comparable small-cap specialty pharma focused on niche generics and branded specialty products across therapeutic areas including GI and infectious disease. Both companies have similar scale, U.S. distribution models, and pipeline-driven growth strategies.

TypeBroad incumbent
Description

Salix is a long-established U.S. gastroenterology specialty pharma (now part of Bausch Health) and was where RedHill's President Rick Scruggs previously built his commercial career. Comparable focus on GI prescription brands distributed through U.S. specialty channels.

TypeEmerging player
Description

Acurx is a similarly small clinical-stage antibiotic developer targeting resistant GI infections, with overlap in microbiome-targeted therapies and antibiotic-resistant bacterial indications. Comparable size, public-micro-cap status, and clinical-stage pipeline approach.

TypeEmerging player
Description

BioXcel is a similarly small U.S. specialty biopharma developing immunology and oncology drugs with FDA designations (Orphan, Fast Track). Comparable pipeline-heavy profile, public-micro-cap market status, and reliance on FDA-designated indications for value creation.

TypeBroad incumbent
Description

Teva is the largest Israeli pharmaceutical company and a historical employer of RedHill's CSO Mark Levitt, where he helped establish Teva's oncology franchise. Comparable in Israeli origin and specialty pharma orientation, though Teva operates at vastly greater scale as a global generics and specialty incumbent.

TypeEmerging player
Description

Innoviva is a specialty pharmaceutical holding company of similar small-cap scale that invests in late-stage development and commercial-stage assets through partnerships. Comparable in leveraging partnerships and licensing arrangements to capture value from clinical-stage programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds21 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RedHill Biopharma

Specialty Pharmaceuticals (Gastroenterology/Infectious Diseases)redhillbio.com

RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company that develops and commercializes oral small molecule therapeutics for gastrointestinal, infectious, and oncological diseases, with one FDA-approved product (Talicia) and a mid-to-late-stage pipeline.

What RedHill Biopharma does

RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company, founded in 2009 and listed on NASDAQ under ticker RDHL, that develops and commercializes proprietary oral small molecule therapeutics for gastrointestinal, infectious, and oncological diseases. Its sole commercial product is Talicia, an FDA-approved oral fixed-dose combination of omeprazole magnesium, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection in adults, listed as a first-line therapy in the 2024 American College of Gastroenterology Clinical Guideline and protected by composition patents through 2042.

The clinical pipeline is anchored by opaganib (ABC294640/Yeliva), a first-in-class investigational oral sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anti-cancer activity, administered to over 470 participants across studies and pursuing indications including prostate cancer (Phase 2 with Bayer/darolutamide), neuroblastoma, cholangiocarcinoma, triple-negative breast cancer, CLL, and Ebola virus disease under FDA Animal Rule development funded by BARDA. Additional pipeline assets include RHB-204 (next-generation oral fixed-dose antibiotic combination targeting MAP-positive Crohn's disease, with FDA Fast Track, Orphan, and QIDP designations), RHB-107/upamostat (a once-daily oral serine protease inhibitor for viral infections and oncology, including pancreatic cancer under Orphan Drug Designation), and RHB-102/Bekinda (extended-release ondansetron for gastroenteritis, gastritis, IBS-D, GLP-1-associated GI intolerance, and oncology-support CINV/RINV indications).

The business model combines Talicia product sales — co-commercialized in the U.S. with Cumberland Pharmaceuticals under a 50/50 net-revenue-share through Talicia Holdings Inc. (in which Cumberland holds a 30% equity stake) — with licensing/milestone revenue (up to $60 million from Hyloris for RHB-102 ex-North America), non-dilutive government funding (BARDA contract for opaganib Ebola development), and recurring equity financings (public offerings, registered direct offerings, convertible notes, and strategic private placements). The company maintains a dual operating footprint with headquarters in Tel Aviv, Israel and U.S. commercial operations in Raleigh, North Carolina.

RedHill Biopharma firmographics

Firmographics
Name
RedHill Biopharma
Legal name
RedHill Biopharma Ltd.
Website
https://redhillbio.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company that develops and commercializes oral small molecule therapeutics for gastrointestinal, infectious, and oncological diseases, with one FDA-approved product (Talicia) and a mid-to-late-stage pipeline.
Ownership category
akta.pro rank

RedHill Biopharma industry classification

Industry
Product category
Specialty Pharmaceuticals (Gastroenterology/Infectious Diseases)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Specialty biopharmaceuticals
  • Gastrointestinal therapeutics
  • Infectious disease drugs
  • Oral small molecules
  • Oncology drug development

Where RedHill Biopharma is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

RedHill Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Talicia Product Sales: Revenue from U.S. sales of Talicia, an FDA-approved treatment for H. pylori infection, co-commercialized with Cumberland Pharmaceuticals with equal net revenue sharing.
  2. Licensing and Milestone Payments: Potential milestone payments and royalties from licensing agreements, including up to $60 million from Hyloris for RHB-102 commercialization outside North America.
  3. Government Funding: U.S. government funding through BARDA for development of opaganib as a medical countermeasure for Ebola virus disease under the FDA Animal Rule pathway.
  4. Strategic Investment: Investment proceeds from private placements and strategic investments, including $4 million from Cumberland Pharmaceuticals for 30% stake in Talicia Holdings Inc.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

RedHill Biopharma product offering

Product offering

Core offering

RedHill Biopharma is a specialty biopharmaceutical company that develops and commercializes proprietary oral small molecule drugs primarily targeting gastrointestinal and infectious diseases, with an expanding pipeline in oncology. The company markets Talicia, an FDA-approved oral fixed-dose combination therapy for H. pylori infection, in the U.S. and UAE, and develops a pipeline of investigational candidates including opaganib (SPHK2 inhibitor), RHB-204 (Crohn's disease antibiotic combination), RHB-107 (serine protease inhibitor), and RHB-102/Bekinda (ondansetron formulation).

Product overview

RedHill Biopharma is a specialty pharmaceutical company with a portfolio of proprietary oral small molecule drugs. The core commercial product is Talicia®, an FDA-approved treatment for H. pylori infection co-commercialized with Cumberland Pharmaceuticals. The R&D pipeline includes: opaganib (first-in-class SPHK2 inhibitor for oncology, viral, and metabolic diseases), RHB-204 (next-generation antibiotic for Crohn's disease), RHB-107 (serine protease inhibitor for viral infections and oncology), and RHB-102/Bekinda® (ondansetron formulation for GI disorders and oncology support). The company focuses on gastroenterology, infectious diseases, and oncology with mid-to-late-stage clinical development programs.

Differentiator

Problem solved

Functional benefit

Brands

  • Talicia: FDA-approved treatment for Helicobacter pylori infection in adults. Oral capsule containing omeprazole magnesium, amoxicillin, and rifabutin. Co-commercialized in U.S. with Cumberland Pharmaceuticals.

Products and services

  • Talicia FDA-approved prescription oral capsule combining omeprazole magnesium, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection in adults. Co-commercialized in the U.S. with Cumberland Pharmaceuticals and distributed through retail pharmacies in the U.S. and UAE.
  • Opaganib (ABC294640, Yeliva) Proprietary first-in-class investigational oral sphingosine kinase-2 (SPHK2) selective inhibitor being developed for multiple oncology, viral, inflammatory, and metabolic indications including prostate cancer, neuroblastoma, cholangiocarcinoma, COVID-19, Ebola virus disease, triple-negative breast cancer, and CLL. Holds FDA Orphan Drug Designations for neuroblastoma and cholangiocarcinoma, and Rare Pediatric Disease Designation for neuroblastoma.
  • RHB-204 Investigational next-generation fixed-dose oral antibiotic combination of clarithromycin, rifabutin, and clofazimine targeting Crohn's disease in MAP-positive patients. Optimized dosing profile from predecessor RHB-104 for enhanced tolerability, safety, and adherence.
  • RHB-107 (Upamostat) First-in-class once-daily oral serine protease inhibitor being developed for viral infections (including COVID-19 and influenza), oncology (pancreatic cancer), and inflammatory gastrointestinal diseases. Host-directed antiviral targeting host cell factors involved in preparing spike protein for viral entry.
  • RHB-102 (Bekinda) Proprietary bimodal immediate and extended-release once-daily oral ondansetron tablet (5-HT3 antagonist) targeting gastroenteritis, gastritis, IBS-D, GLP-1/GIP-associated GI intolerance, and oncology support indications including chemotherapy-induced and radiation-induced nausea and vomiting (CINV/RINV). Pursuing FDA approval through 505(b)(2) regulatory pathway.

Quantifiable outcome

  • Opaganib demonstrated 70.2% mortality reduction in Phase 3 COVID-19 study
  • +3 more outcomes

Companies that use RedHill Biopharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

RedHill Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

RedHill Biopharma partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor and core.

  • Penn State University / Apogee BiotechnologyminorStrategic or Co-development Partner · 1 January 2026Research collaboration for preclinical studies demonstrating opaganib's effects in neuroblastoma models, showing enhancement of chemotherapy efficacy by destabilizing n-Myc oncogenic driver.
  • University of KansasminorStrategic or Co-development Partner · 1 January 2026Research collaboration showing pre-treatment with opaganib followed by low-dose diABZI potentiates STING-mediated effects and may augment anti-tumor immunity in triple-negative breast cancer.
  • Cumberland Pharmaceuticals Inc.coreGTM or Marketing Partner · 1 October 2025Strategic partnership including $4 million investment for 30% equity stake in newly formed Talicia Holdings Inc. and U.S. co-commercialization agreement for Talicia. Cumberland handles distribution and sales while sharing net revenues equally with RedHill. Partnership aims to enhance Talicia's market penetration and operational efficiency in the U.S.
  • Hyloris Pharmaceuticals SAcoreOEM/ Whitelabel/ Licensing Partner · 1 February 2025Exclusive worldwide development and commercialization licensing agreement, excluding North America, for RHB-102 (Bekinda). RedHill receives up to $60 million in potential milestone payments plus royalties. Hyloris advances development for oncology support (CINV/RINV) in the UK and other territories.
  • Bayer AGcoreStrategic or Co-development Partner · 1 January 2025Bayer provides financial support for Phase 2 study evaluating opaganib in combination with Bayer's darolutamide in men with metastatic castration-resistant prostate cancer (mCRPC). Study led by Professor Lisa Horvath from Chris O'Brien Lifehouse and ANZUP cancer trials group.
  • Ramsay Hospital Research FoundationminorStrategic or Co-development PartnerResearch foundation supporting the Phase 2 study of opaganib in combination with darolutamide for advanced prostate cancer.
  • ANZUP (Australian and New Zealand Urogenital and Prostate Cancer Trials Group)minorStrategic or Co-development PartnerClinical trials group leading the Phase 2 study of opaganib in advanced prostate cancer, registered with Australian New Zealand Clinical Trials Registry.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

RedHill Biopharma competitors and assessment

Company assessment

Direct peers

  • Cumberland Pharmaceuticals: Cumberland is RedHill's direct U.S. co-commercialization partner for Talicia and holds a 30% equity stake in Talicia Holdings Inc. Both are small-cap U.S.-focused specialty pharmaceutical companies targeting gastroenterology and infectious disease, with similar sales models and pipeline-heavy business profiles.
  • Phathom Pharmaceuticals: Phathom directly competes with RedHill in H. pylori infection with Voquezna (vonoprazan-based regimens), a newer branded alternative to Talicia. Both companies are U.S.-focused specialty pharma players concentrating on gastroenterology with first-line guideline-listed therapies.
  • Hyloris Pharmaceuticals: Hyloris is RedHill's worldwide ex-North America licensing partner for RHB-102 (Bekinda) and operates a similar business model: a small specialty pharma that in-licenses, reformulates, and partners established molecules for niche indications. The two share a comparable pipeline-light, partnership-heavy commercialization approach.
  • Eagle Pharmaceuticals: Eagle Pharmaceuticals is a small-cap specialty pharma with similar business model attributes (505(b)(2) reformulations, hospital/specialty channels) and is led by executives who previously held senior roles at RedHill, including former CBO Guy Goldberg. Direct overlap in specialty injectable and hospital-focused product strategies.
  • ANI Pharmaceuticals: ANI is a comparable small-cap specialty pharma focused on niche generics and branded specialty products across therapeutic areas including GI and infectious disease. Both companies have similar scale, U.S. distribution models, and pipeline-driven growth strategies.

Broad incumbents

  • Salix Pharmaceuticals: Salix is a long-established U.S. gastroenterology specialty pharma (now part of Bausch Health) and was where RedHill's President Rick Scruggs previously built his commercial career. Comparable focus on GI prescription brands distributed through U.S. specialty channels.
  • Teva Pharmaceutical Industries: Teva is the largest Israeli pharmaceutical company and a historical employer of RedHill's CSO Mark Levitt, where he helped establish Teva's oncology franchise. Comparable in Israeli origin and specialty pharma orientation, though Teva operates at vastly greater scale as a global generics and specialty incumbent.

Emerging players

  • Acurx Pharmaceuticals: Acurx is a similarly small clinical-stage antibiotic developer targeting resistant GI infections, with overlap in microbiome-targeted therapies and antibiotic-resistant bacterial indications. Comparable size, public-micro-cap status, and clinical-stage pipeline approach.
  • BioXcel Therapeutics: BioXcel is a similarly small U.S. specialty biopharma developing immunology and oncology drugs with FDA designations (Orphan, Fast Track). Comparable pipeline-heavy profile, public-micro-cap market status, and reliance on FDA-designated indications for value creation.
  • Innoviva: Innoviva is a specialty pharmaceutical holding company of similar small-cap scale that invests in late-stage development and commercial-stage assets through partnerships. Comparable in leveraging partnerships and licensing arrangements to capture value from clinical-stage programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

RedHill Biopharma social profiles

Digital presence

RedHill Biopharma compliance and trust

Trust signal

Compliance7 records

RedHill Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RedHill Biopharma leadership team

Management profile

Number of profiles

Profiles10 records

RedHill Biopharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

RedHill Biopharma funding detail

Funding detail

Funding overview

Funding rounds21 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RedHill Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RedHill Biopharma

What does RedHill Biopharma do?

RedHill Biopharma is a specialty biopharmaceutical company that develops and commercializes proprietary oral small molecule drugs primarily targeting gastrointestinal and infectious diseases, with an expanding pipeline in oncology. The company markets Talicia, an FDA-approved oral fixed-dose combination therapy for H. pylori infection, in the U.S. and UAE, and develops a pipeline of investigational candidates including opaganib (SPHK2 inhibitor), RHB-204 (Crohn's disease antibiotic combination), RHB-107 (serine protease inhibitor), and RHB-102/Bekinda (ondansetron formulation).

Is RedHill Biopharma a public or private company?

RedHill Biopharma is a public company. It is classified as public and is currently operating.

When was RedHill Biopharma founded?

RedHill Biopharma was founded in 2009. It employs 11 to 50 people.

Where is RedHill Biopharma based?

RedHill Biopharma is headquartered in Tel Aviv, Israel, in the Middle East region.

How does RedHill Biopharma make money?

Four revenue lines are on record. Talicia Product Sales are the primary driver. The others are licensing and Milestone Payments, government Funding and strategic Investment.

Who are RedHill Biopharma's main competitors?

Direct peers on record are Cumberland Pharmaceuticals, Phathom Pharmaceuticals, Hyloris Pharmaceuticals, Eagle Pharmaceuticals and ANI Pharmaceuticals. Broad incumbents are Salix Pharmaceuticals and Teva Pharmaceutical Industries. Emerging players are Acurx Pharmaceuticals, BioXcel Therapeutics and Innoviva.

Does RedHill Biopharma have an API?

No public API is recorded for RedHill Biopharma.

What industry is RedHill Biopharma in?

RedHill Biopharma's product category is Specialty Pharmaceuticals (Gastroenterology/Infectious Diseases). Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanRedHill Acquires Commercial Rights to Rebyota, ClenpiqRedHill Biopharma announced that its Chief Business Officer discussed the company's strategic transformation, including the acquisition of commercialization rights to Rebyota and Clenpiq, in a virtual investor segment. The company aims to accelerate growth across its expanded gastrointestinal portfolio using its lean infrastructure and physician relationships.Ticker ReportRedhill Biopharma (NASDAQ:RDHL) versus Astrazeneca (NYSE:AZN) Head-To-Head ReviewAstrazeneca outperforms Redhill Biopharma across nine of eleven factors, including revenue, profitability, and analyst ratings. Astrazeneca's revenue is $58.74 billion versus Redhill's loss of $430,000, and its consensus target price implies 29.68% upside. Astrazeneca's beta of 0.27 indicates lower volatility than Redhill's 4.91.American Banking and Market NewsRedhill Biopharma (NASDAQ:RDHL) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL) Financial ComparisonRedhill Biopharma and Zentalis Pharmaceuticals are compared on financial metrics, analyst ratings, and risk. Zentalis has a stronger consensus rating and higher upside, while Redhill beats on 7 of 11 factors. Both are small-cap biopharmaceuticals with distinct pipelines.American Banking and Market NewsComparing Cyclerion Therapeutics (NASDAQ:CYCN) and Redhill Biopharma (NASDAQ:RDHL)Cyclerion Therapeutics and Redhill Biopharma are compared on revenue, profitability, and analyst ratings. Redhill has lower revenue but higher earnings, and beats Cyclerion on 6 of 9 factors. Both have sell ratings and low institutional ownership.American Banking and Market NewsRedhill Biopharma (NASDAQ:RDHL) vs. Astrazeneca (NYSE:AZN) Financial ReviewAstrazeneca beats Redhill Biopharma on 9 of 12 financial factors, including higher revenue ($58.74B vs $290K) and earnings ($10.22B vs -$430K). Astrazeneca has a consensus target price of $206.67 with 29.02% upside, while Redhill Biopharma has no target. Astrazeneca's beta of 0.27 indicates lower volatility than Redhill's 4.91.Defense WorldComparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)Zentalis Pharmaceuticals and Redhill Biopharma are compared on valuation, profitability, and analyst ratings. Zentalis has a lower price-to-earnings ratio and a stronger consensus rating with a $7.50 price target, implying 169.78% upside. Redhill Biopharma beats Zentalis on 9 of 13 factors.Ticker ReportRedhill Biopharma (NASDAQ:RDHL) Shares Break Below 200 Day Moving Average – What’s Next?Redhill Biopharma shares fell below their 200-day moving average on Friday, trading at $0.50. Weiss Ratings reiterated a sell rating, and the stock has an average analyst rating of Sell. Gagnon Securities increased its stake by 383.1% in Q4.Markets DailyAstrazeneca (NYSE:AZN) & Redhill Biopharma (NASDAQ:RDHL) Financial AnalysisAstrazeneca beats Redhill Biopharma on 10 of 14 factors, including institutional ownership, analyst ratings, and profitability. Astrazeneca has a consensus price target of $206.67, implying 31.71% upside, while Redhill Biopharma is more affordable but riskier. Astrazeneca's beta of 0.27 indicates lower volatility than Redhill's 4.91.Markets DailyHead-To-Head Comparison: Redhill Biopharma (NASDAQ:RDHL) vs. Cyclerion Therapeutics (NASDAQ:CYCN)A head-to-head comparison of Redhill Biopharma and Cyclerion Therapeutics evaluates profitability, valuation, and analyst ratings. Redhill Biopharma beats Cyclerion on 8 of 11 factors, including higher earnings and lower P/E ratio. Cyclerion has stronger institutional ownership at 75.6% versus 7.2%.Markets DailyRedhill Biopharma (NASDAQ:RDHL) & Zentalis Pharmaceuticals (NASDAQ:ZNTL) Critical ReviewZentalis Pharmaceuticals and Redhill Biopharma are compared on risk, valuation, profitability, and analyst ratings. Zentalis has a stronger consensus rating, higher upside, and lower volatility, while Redhill beats on nine of thirteen factors. Analysts favor Zentalis, citing a $6.75 price target and 167.86% upside.